New phase 3 data has shown Sanofi’s diabetes combination therapy, LixiLan (insulin glargine+lixisenatide), met blood sugar targets in two pivotal phase 3 trials as the French company prepares ...

Inclusion of basal insulin glargine in multiple daily injection (MDI) regimens decreases glycemic variability in adolescents with type 1 diabetes mellitus (T1DM), according to US researchers.

Such forward looking statements may include statements about the approval for the first interchangeable biosimilar Semglee (insulin glargine-yfgn injection) for the treatment of diabetes ...